Splash

COPD

COPD damages the airways and lungs, leading to progressive debilitating breathlessness.
Splash
COPD

COPD has a devastating impact. Patients struggle with basic daily activities such as getting out of bed, showering and walking. We urgently need better treatments.

COPD is not a single disease. It covers a group of lung conditions including chronic bronchitis and emphysema. All of these conditions are characterized by chronic inflammation of the airways. Total annual direct medical costs relating to COPD in the United States are projected to rise to approximately $50 billion in 2020. Global sales of drugs currently indicated for COPD are estimated to be $15.6 billion in 2019.

384m

People

Worldwide suffer from COPD

3rd

Biggest Killer

COPD is expected to be the third leading cause of death worldwide by 2030

$15.6

Billion

Global estimated sales of COPD drugs

COPD patients are commonly treated with bronchodilators, to relieve airway constriction and make it easier to breathe, and corticosteroids, to reduce lung inflammation. More severe patients with recurrent exacerbations, sudden severe flare-ups of symptoms, are often treated with an oral formulation of an anti-inflammatory PDE4 inhibitor. Despite the wide availability of these therapies, many COPD patients continue to suffer exacerbations, which are estimated to cause approximately 1.5 million emergency department visits, 687,000 hospitalizations and 129,000 deaths per year in the United States alone. Furthermore, current therapies have not changed the progressive decline in lung function or reduced the mortality associated with COPD. An urgent and unmet medical need exists for new and more effective COPD treatments to reduce the number and burden of symptoms and exacerbations.

Splash

© Verona Pharma plc 2020. All rights reserved